US FDA Approved First Geographic Atrophy Drug by Apellis
One of Fierce Pharma’s best three most expected drug dispatches of 2023 were likewise one of the year’s generally questionable. However, Apellis Pharmaceuticals achieved a second commercial approval for its C3 inhibitor pegcetacoplan on Friday, defying the industry’s losing trend in geographic atrophy (GA). The first treatment for GA, an advanced stage of age-related macular […]
Continue Reading